Combination Checkpoint Inhibitor Therapy in Advanced Melanoma

This study investigates the combination of nivolumab and ipilimumab as first-line treatment for patients with unresectable or metastatic melanoma. The primary endpoint is overall survival.

Trial Details

NCT ID
NCT06456789
Phase
Phase 3
Sponsor
Bristol-Myers Squibb
Status
RECRUITING
Cancer Type
Melanoma
Locations (sample)
  • New York, New York
  • Rochester, Minnesota
  • Nashville, Tennessee
  • San Diego, California

Key Eligibility Criteria

  • Age 18 years or older
  • Unresectable or metastatic melanoma
  • No prior systemic therapy for advanced melanoma
  • ECOG performance status 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →